Eighty-five schizophrenic patients being seen on a regular basis in an outpatient clinic were interviewed about information given to them concerning their treatment. The patients were asked about risks and side effects of neuroleptics, coping strategies in regard to side effects, therapeutic effects and diagnosis, knowledge about therapy, and personal evaluation of their information. The results are discussed with respect to both the legal and therapeutic aspects of patients' information. Issues considered include the extent to which highly compliant patients know important facts about their treatment, how satisfied they are with the information given to them, and the implications for informed consent.
Over the past decade, there has been a growing awareness of problems concerning the information given to patients about the risks and benefits of the therapy they receive. This trend is reflected in a growing number of court cases in which physicians have been found liable for their failure to provide sufficient information to their patients or to obtain valid informed consent from them (Brugmann 1977; Meisell, Roth, and Lidz 1977) .
In addition to legal considerations, there is some evidence that an effort to inform patients more fully might enhance treatment response by increasing cooperation (Linden 1979) . In principle, there is little controversy about the importance of ensuring informed consent, but there are numerous problems in defining this concept.
Is a patient really informed unless he can pass a test on the information he was given? And exactly what facts should be presented to him? Currently, there is almost no empirically based knowledge about the kind of information-in what way, in what amount, and at what time-that should be given to which patient to fulfill legal and therapeutic requirements.
In the present study, schizophrenic patients who had been in therapy for many years were interviewed about the information they received. Key questions were how much patients knew about their treatment and how satisfied they were with the information that had been given to them. It was hoped that a systematic assessment of the information these patients possessed would give some point of reference for discussing legal and therapeutic demands more specifically and in greater detail.
Population
The 85 patients (40 percent male, 60 percent female; age range 20-75 years) who were interviewed were being seen on a reguar basis in the outpatient clinic of the Department of Psychiatry, Free University of Berlin (mean duration of treatment at the clinic = 10.5 ± SD 8.1 years). The age of onset of illness ranged from 15 to 58, with 1 to 18 episodes of relapse.
All patients had been diagnosed by attending psychiatrists as suffering from one of the schizophrenic disorders (ICD-295; World Health Organization 1967) . The population of the clinic has been described in greater detail elsewhere (Goncalves 1978) . Investigations of medication serum levels suggest that the patients are highly compliant in taking the various kinds of neuroleptics that have been prescribed for them (Pietzcker et al. 1978) .
Method
The patients were interviewed by the authors who used a detailed interview guide and questionnaire. The questions were set up in such a way that there was little doubt about the patients' answers. In several checks, interrater reliability was consistently higher than 95 percent agreement.
All patients who were asked to participate in the study agreed to do so. The average interview took 15 to 20 minutes.
Results
Asked which side effects their drugs might have, 40 percent of the patients could not name a single side effect, 1 percent named one, 23 percent named two to three, and 6 percent named four to five side effects. The side effects that were spontaneously mentioned most frequently were drowsiness by 33 percent of patients, and stiffness of muscles by 7 percent.
The patients were then given a list of 37 typical side effects of neuroleptics and other drugs; terminology was both lay and scientific (taken from package inserts). Among the side effects that were selected as having been experienced during the course of treatment, drowsiness was again most often named (see table 1 ). The mean number of side effects selected by a patient from among the 37 items listed was 6.7 (range 0-28, SD = 5.9).
Patients were then asked to check those side effects that might possibly occur, but, on average, checked only two additional side effects; almost half (46 percent) of the patients did not name any further side effects. The most frequently selected potential side effects were impairment of driving ability (22 percent), dry mouth (13 percent), impairment of working ability (12 percent), and blurred vision (11 percent).
A final question on this topic asked patients to identify side effects they considered to be serious. Seriousness was defined as being either unbearable or dangerous so that the particular side effect, if it occurred, could not be ignored but would necessitate countermeasures. The mean number of side effects nominated by the patients as serious was two. The side effects named most often were mainly ones that were subjectively tiresome or troublesome to the patient ( 2 ). Most of these strategies must be seen as problematic and therefore might indicate the need for better patient education in this area.
A related question concerns the information patients receive about precautions which should be taken when on medication. Forty-eight percent of the patients pointed out that they should be careful with alcohol, 6 percent mentioned seda- rives, and 15 percent correctly mentioned miscellaneous other drugs-for example, psychostimulants.
Knowledge About Therapeutic Effects. The fact that the principal therapeutic effects, in most cases, can be equated with the absence of negative illness effects makes this topic difficult to discuss. Nevertheless, talking about therapeutic effects seems to be crucial, because there is some evidence that knowledge about these effects can influence therapeutic compliance. Parkes, Brown, and Monck (1962) found that patients who stopped taking drugs saw no reason for continuing; and Francis, Korsch, and Morris (1969) showed that therapeutic compliance improved when patients recognized their illness as a severe one and as one that needed treatment.
When asked why they needed medication or what benefits they hoped the medication might have, 85 percent of the patients mentioned at least one therapeutic effect spontaneously. Thirty-nine percent said that their drugs were given to prevent relapse. Interestingly, the ratio of patients naming one or more therapeutic effects vs. those giving none was 5:7-considerably higher than the corresponding 1:5 ratio for side effects. Nevertheless, 48 percent mentioned only one therapeutic effect spontaneously, and no one gave more than four.
Presenting a list of therapeutic effects was a second way of assessing the reasons patients had for taking their medication (see table 3). When asked which of the 37 therapeutic effects listed they had experienced personally, patients checked a mean of 12 items (range 0-36, SD = 9.5)-a mean more than double that for side effects. This finding must be interpreted carefully, however, because the side effects describe more clearly defined states than the list of therapeutic effects. Therefore, it might be easier to select one of the therapeutic effects than one of the side effects. When patients were asked about additional benefits that could possibly occur, there was little further response. Fifty-eight percent could not name even one additional therapeutic effect. The mean number of potential therapeutic effects named was 1.4 (± SD 3.0).
As shown in table 3, prevention of relapse and sedation were the therapeutic effects most often recognized by patients. Some effects that would be considered typical benefits of neuroleptic treatment were mentioned by relatively few patients. These are, for example, realistic self-perception (23 percent), clearer thinking (21 percent), fewer problems with other people (21 percent), better concen- When asked which of the therapeutic effects listed would be indispensable for therapeutic success in their own cases, patients selected exactly the same effects they had actually experienced (table 3) . Only 15 percent checked more therapeutic effects as important than they had checked as experienced.
In general, patients seemed to perceive their treatment as beneficial. Eighty-four percent stated that their illness had to be considered as severe, 87 percent felt it could be improved by drug therapy, and 74 percent rejected the idea that drug therapy could be of minor importance for them.
These statements were made despite the fact that only 52 percent could correctly name their illness as paranoid psychosis or schizophrenia. The remainder used other terms (see table 4) to identify their illness, with "nervous breakdown" being most frequently mentioned-in 25 percent of cases.
Of the patients who knew their correct diagnosis, 51 percent said they had obtained this information from their doctors. The second main source of information for the patients (accounting for more than 30 percent of informed patients) seemed to be legal and administrative activities of various kinds such as hospital admission papers, court commitments, revocations of driver's licenses, or handicap certification. The rest received their information from friends, nurses, and books. Fourteen percent did not know where they had learned their diagnoses.
Knowledge About Therapy. A surprisingly high 93 percent of all drugs prescribed were named correctly by the patients. Patients who received more than one drug-50 percent of the total group-were asked which drug was most important. All but one patient named the neuroleptics as the most important; the single exception named biperiden.
Another point that might be regarded as therapeutically relevant is the name of the class of drugs to which the prescribed drug belongs. Thoughts about drug class suggest thoughts about therapeutic indications. Only 15 percent knew that their drugs were neuroleptics. Sixty-three percent made no comment on drug class, and the rest tended to emphasize sedative drug actions, applying such terms as "quieting drugs," "sedatives," and "sleeping drugs."
One important area of knowledge to be considered is the patient's time perspective about the course of treatment and, especially, about the conditions under which drug treatment may be stopped. In this population, 52 percent clearly indicated their expectation that therapy would continue for years, if not forever. About 10 percent of the patients obviously were thinking about ending drug treatment in less than 6 months-in all cases contrary to their psychiatrists' advice. Forty percent said that they did not know when their treatment might be ended, although at this point in the interview it was strongly requested that the patient give an answer.
The question was then presented in a different way. Patients were asked whether they felt they were able to decide when there was no longer a need for them to take medication and, thus, could decide for themselves when to stop medication. Seventy-nine percent denied being able to do that and said they would only stop medication after discussing the matter with their doctor. Therefore, it might be concluded that not knowing when to end treatment, at least in this population, can be equated with being prepared to continue treatment for a while depending on the doctor's recommendation.
Patients' Evaluations of Their Information. As a rough measure of the patients' subjective feelings about their knowledge and the quality of information they had received, two questions were posed. Eighty percent of the patients felt that patients in general were adequately informed. This percentage dropped to 54 percent when patients were asked whether they themselves had been adequately informed about therapy. If provided with a list of side effects and therapeutic effects, patients make considerably more responses. As it turns out, however, these are dependent on what the patient has experienced, not on what he has been told. Basically, the only exception to that rule was the patients' knowledge about possible impairment of driving ability. Even in that case, the absolute percentage of patients who were aware of this potential problem (i.e., 30 percent) must be viewed as fairly low.
These findings cast considerable doubt on the usefulness of formal legal demands concerning information given to patients. Real consent, as expressed in the patient's behavior in following through voluntarily with a treatment for 10 years, is one thing; knowledge of medical facts is obviously another. If future legal development in the area of informed consent concentrates on the valid basis of therapeutic decision making by the patient, further research on these decision-generating factors would appear to be more constructive than the development of even longer informed consent forms (Epstein and Lasagna 1969; Laforet 1976) .
A major question is whether certain kinds of information influence patient cooperation and therapeutic compliance. Blackwell (1979) speculated that "possibly two thirds of the real problems in adherence stem from faulty comprehension." Thus, an emphasis on patient education could be of considerable importance in the doctorpatient relationship. It should be noted that this approach could be one of the more readily available means of helping patients to achieve high compliance (MacDonald, MacDonald, and Phoenix 1977) . Nevertheless, it is obvious that decisions about the information to be provided to patientswhat kind, how much, and how detailed -must be empirically based. Toward this end, it will be necessary to investigate different populations-for example, compliant vs. noncompliant patients.
Regarding the evaluation of the present data, there seem to be two points of reference. The first is what the patients themselves think about their information. A relatively high number (40 percent) do not feel themselves sufficiently informed. This finding is of particular interest as it could obviously apply to patients who have known their doctors for quite some time. Even long-established doctorpatient relationships do not necessarily lead to patients' satisfaction with the information supplied to them.
A second point is the fact that the population studied is a highly compliant one. Attending the clinic, a research institute, means more inconvenience and more supervision for the patient than would usually be true in a normal private practice, an easily available alternative. Despite this, the patients have continued attending the clinic for more than 10 years.
Thus, findings in this sample probably have most implications for other populations of highly compliant patients.
It is significant that 93 percent of patients knew the correct names of the drugs prescribed for them. Almost 100 percent knew which of the drugs they received were the primary therapeutic agents in their treatment. Also of interest are the patients' long-term expectations: Almost 80 percent expected that their treatment would go on for years. The patients also appeared to incorporate the doctor's opinion into their decision about continuation of therapy. Almost 80 percent thought that they themselves were not able to decide when to stop medication and that they would need to depend upon the doctor's advice. Similarly, about 80 percent of patients recognized their need for drug therapy and acknowledged that their condition was improved by medication. Last, but not least, patients seemed to be well informed about the organizational details of their therapy. Ninety-six percent knew when their next doctor's appointment was scheduled, and 100 percent knew their doctor's name (a fact that should be considered in the context of a clinic system staffed with several doctors who sometimes fill in for one another and who are replaced from time to time).
Which areas of information yield special problems? As pointed out, the patient may not recognize some very significant therapeutic effects. There should be, for example, more than 20 percent of schizophrenic patients whose thinking ability improved under neuroleptic therapy. It might be speculated that for these patients the last ex-perience of thinking disorders occurred too long ago to be vividly remembered, or alternatively that the sedative actions of neuroleptic drugs make it difficult for some patients to recognize certain therapeutic benefits. In any case, the help of the psychiatrist seems necessary to remind the patient why he goes on with his therapy.
To this same area of recognition of therapeutic effects belongs the knowledge of drug class. As shown, many patients conceptualize the neuroleptics incorrectly as "quieting drugs." This misconception may handicap patients in acknowledging the real reasons for their treatment. This same argument might be applied to the names patients used for their illness. As an example, if a patient thinks his illness was a "nervous breakdown" and that his medication is a "sedative," then it seems only logical to stop medication when a reduction in drive becomes obvious, which actually could be a consequence of the psychosis.
Another problematic area where patients might need more help is that of side effects. Two problems emerge from these data. First, patients conceptualize those side effects as serious which they themselves have experienced. Though understandable, such thinking is not therapeutically helpful. From stress theory it is well established that the negative impact of a stressor depends on, among other variables, the cognitive interpretation of the stimulus (Beck and Rush 1975) . If patients consider occurring side effects as "severe," they will suffer from more stress than if they could more effectively classify side effects into groups such as severe vs. nonsevere, tolerable, negligible, and so on. On the other hand, side effects that are truly severe but not subjectively impressive could be overlooked by a patient who is not aware of their possible occurrence.
Noteworthy in regard to the main topic of this article is an examination of the list of side effects relative to those side effects that occur in long-term neuroleptic therapy. As can easily be seen, "drowsiness" is by far the most often experienced negative effect, followed by "dry mouth." This finding is concordant with other reports such as Rickels et al. (1978) . In regard to patient information, it would be of special interest to help the patient cope with the interference of drowsiness in his daily activities. Almost two out of three patients suffer from this side effect. Therefore, it might be wise to ask every patient about problems related to drowsiness, even if he does not mention them on his own.
In this discussion it has not been possible to cover all the questions and problems associated with the data presented. An examination of the interrelations of certain data and their prognostic value is forthcoming.
